BRK-B vs C
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The deterministic health profile is weak, highlighted by a Piotroski F-Score of 3/9, indicating deteriorating operational efficiency and profitability trends. While the company maintains a fortress balance sheet with a Debt/Equity ratio of 0.19 and a Current Ratio of 7.07, the stock is trading at a significant premium to its growth-based intrinsic value of $217.21. Negative YoY revenue and earnings growth, coupled with a bearish technical trend, offset the positive analyst sentiment and long-term historical performance.
Citigroup presents a stark contradiction between market momentum and fundamental health. While the current price of $126.28 is well-supported by the Graham Number ($131.63), the Piotroski F-Score of 2/9 indicates severe fundamental weakness and deteriorating financial health. Despite a massive 1-year price surge of 104.9%, the company is facing negative earnings growth (-10.8% YoY) and bearish insider sentiment, including sales by the CFO. The stock is currently trading at a significant premium to its growth-based intrinsic value ($49.0), suggesting the market is pricing in a recovery that is not yet reflected in the data.
Compare Another Pair
Related Comparisons
BRK-B vs C: Head-to-Head Comparison
This page compares Berkshire Hathaway Inc. (BRK-B) and Citigroup Inc. (C) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.